Latest release delivers expanded modeling capabilities, improved computational performance, and greater reproducibility for advanced pharmacometric workflows
DOVER, DEL. (November 6, 2026) — PumasAI, an AI-powered clinical pharmacology and pharmacometrics company transforming how pharmaceutical teams work, today announced the release of Pumas 2.9, introducing significant enhancements that improve computational performance, estimation stability, reproducibility, and support for increasingly sophisticated pharmacometric workflows.
Building on the artificial intelligence (AI) capabilities
introduced in Pumas 2.8 through PumasAide,
the latest release strengthens the scientific engine that powers modern
model-informed drug development. Pumas 2.9 delivers improvements across
estimation methods, model flexibility, diagnostics, distributed computing, and
user experience, helping pharmaceutical and biotechnology organizations analyze
complex data with greater confidence and efficiency.
"Pumas was built to help scientists solve increasingly
complex problems without adding unnecessary complexity to their
workflows," said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI.
"Pumas 2.9 continues that mission by strengthening the core modeling
platform with faster computation, greater stability, and expanded capabilities
that allow researchers to spend more time generating scientific insight."
Major enhancements in Pumas 2.9 include:
● Expanded Advanced Estimation, with continued
enhancements to the experimental Monte Carlo Expectation Maximization (MCEM)
and Variational Expectation Maximization (VEM) estimation methods improve
stability, reliability, and support for increasingly complex nonlinear
mixed-effects models. ● Improved Computational Performance,
incorporating new multithreading capabilities, distributed computing
enhancements, and intelligent load balancing accelerate simulations,
diagnostics, inference, and estimation across demanding modeling workflows. ● Greater Reproducibility, bringing improvements
to deterministic calculations and reproducible inference across parallel
computing environments help ensure greater consistency and confidence in
scientific results. ● Expanded
Modeling Flexibility, with new support for ordered parameter domains,
enhanced covariate selection, richer prediction outputs, expanded error model
capabilities, and additional inference tools provide scientists with greater flexibility
when building sophisticated pharmacometric models. ● Enhanced
User Experience, including Improved diagnostics, clearer documentation,
expanded error reporting, and numerous workflow refinements simplify model
development while helping users identify and resolve issues more efficiently.
Pumas continues to provide pharmaceutical and
biotechnology organizations with a single integrated platform for clinical
pharmacology and pharmacometrics, allowing teams to perform nonlinear
mixed-effects (NLME) modeling, optimal design, Bayesian analyses, SAEM, Monte
Carlo Expectation Maximization (MCEM), Variational Expectation Maximization
(VEM), clinical trial simulation, machine learning, noncompartmental analysis,
and bioequivalence studies within one unified software environment.
By eliminating fragmented workflows across multiple software
platforms, organizations can reduce operational complexity, accelerate
analyses, and dedicate more time to scientific decision-making throughout the
drug development lifecycle.
"Every release of Pumas is driven by the
same objective," added Ivaturi. "Our responsibility is to give
scientists the most advanced computational tools available while making those
tools faster, more reliable, and easier to use. As clinical pharmacology
continues to evolve, we remain committed to delivering innovations that help
researchers ask better questions, explore more possibilities, and accelerate
the development of new therapies."
Pumas 2.9 is available through the fully validated JuliaHub
cloud environment and for desktop deployment. Students, professors, and
academic researchers may also receive complimentary access for non-commercial
education and research.
For additional information about Pumas 2.9, visit https://pumas.ai/our-products/pumas.
About PumasAI
PumasAI is an award-winning global healthcare intelligence
company with a vision to accelerate precision healthcare to patients.
Proprietary software and AI tools developed by the company includes the Pumas
suite of products, an integrated modeling and simulation platform designed to
multiply productivity across the drug development lifecycle. Scientists at
PumasAI provide consulting with leading pharmaceutical innovators in clinical
pharmacology, model-informed drug development (MIDD), pharmacometrics,
front-end applications, and more.
For additional information, visit www.pumas.ai
Media Contact Don F. McLean, McLean Media +1-734-716-4182
